

SPSS

SCI 6

Meta



17757729260

221010@xxmu.edu.cn

2010/09-2015/06

2015/09-2018/06

2018/09-2022/06

2022/07

1. PRMT5

PDCD4

2024.01- 2026.12 30

1. Liang Z, Xue C, Chen Q, Li M, Li G, Feng H, Liu Y, Liu X, Ma S. Screening of prognostic biomarkers for Stereotactic Body Radiation Therapy in liver cancer. *Dose-Response*. 2022 May 6;20(2):15593258221097589.

2. Liang Z, Liu L, Wen C, Jiang H, Ye T, Ma S, Liu X. Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis. *Cancer Control*. 2021 Jan-Dec;28:10732748211050583.

3. Liang Z, Wen C, Jiang H, Ma S, Liu X. Protein Arginine Methyltransferase 5 Functions via Interacting Proteins. *Front Cell Dev Biol*. 2021 Aug 27; 9:725301.

4. Liang Z, Xin R, Yu Y, Wang R, Wang C, Liu X. Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies. *World J Urol*. 2018;36(9):1373-1381.

5. Liang Z, Zhang Q, Wang C, Shi F, Cao H, Yu Y, Zhang M, Liu X. Hyaluronic acid/ Hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis. *Neoplasma*. 2017;64(6):901-908. 6. Liang Z, Liu X, Zhang Q, Wang C, Zhao Y. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. *Dig Liver Dis*. 2016 Oct;48(10):1227-32